Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of AZD0837 versus warfarin in atrial fibrillation
2004-000359-41Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of atecegatran metoxil in Atrial fibrillation (AFib) (3 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD0837 vs warfarin over 3 months and Pharmacokinetics of AR-H067637XX. Started Jul 2004; status: completed.
02
Drugs
atecegatran metoxil
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2004-000359-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000359-41.